Published Papers & Misc - Akihiro HIRAKAWA

Division display  241 - 260 of about 274 ／  All the affair displays >>

  1. Hirano K, Ohgomori T, Kobayashi K, Tanaka F, Matsumoto T, Natori T, Matsuyama Y, Uchimura K, Sakamoto K, Takeuchi H, Hirakawa A, Suzumura A, Sobue G, Ishiguro N, Imagama S, Kadomatsu K. Ablation of keratan sulfate accelerates early phase pathogenesis of ALS PLoS ONE. 2013.06; 25 (8): e66969.

  2. Sato Y, Kawataki M, Hirakawa A, Kato T, Itani T, Hayakawa M. The diameter of the inferior vena cava provides a noninvasive way of calculating central venous pressure in neonates Acta Paediatrica. 2013.06; 102 (6): e241-e246.

  3. Hirakawa A, Hamada C, Matsui S.. A dose-finding approach based on shrunken predictive probability for combinations of two agents in phase I trials. Statistics in Medicine. 2013.05; 32 (26): 4515-4525.

  4. Kobayashi K, Imagama S, Ohgomori T, Hirano K, Uchimura K, Sakamoto K, Hirakawa A, Takeuchi H, Suzumura A, Ishiguro N, Kadomatsu K. Minocycline selectively inhibits M1 polarization of microglia Cell Death & Disease. 2013.03; 7 (4): e525.

  5. Tanabe Y, Hashimoto K, Shimizu C, Hirakawa A, Harano K, Yunokawa M, Yonemori K, Katsumata N, Tamura K, Ando M, Kinoshita T, Fujiwara Y. Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer International Journal of Clinical Oncology. 2013.02; 18 (1): 132-138.

  6. Asano J, Hirakawa A, Hamada C, Yonemori K, Hirata T, Shimizu C, Tamura K, Fujiwara Y. Use of Cox’s cure model to establish clinical determinants of long-term disease-free survival in breast cancer patients treated with neoadjuvant chemotherapy International Journal of Breast Cancer. 2013;

  7. Asano J, Hirakawa A, Hamada C. . A stepwise variable selection for a Cox proportional hazards cure model with application to breast cancer data. Japanese Journal of Biometrics,. 2013; 34 (1): 21-34.

  8. Kojima Y, Hashimoto K, Ando M, Hirakawa A, Yonemori K, Kodaira M, Yunokawa M, Shimizu C, Tamura K, Katsumata N, Hosono A, Makimoto A, Fujiwara Y. Clinical outcomes of adult and childhood rhabdomyosarcoma　treated with vincristine, d-actinomycin, and cyclophosphamide chemotherapy Journal of Cancer Research and Clinical Oncology. 2012.07; 138 (7): 1249-1257.

  9. Kaneko S, Hirakawa A, Hamada C.. Gene selection using a high-dimensional regression model with microarrays with cancer prognostic studies. Cancer Informatics. 2012.07; 11 29-39.

  10. Hirakawa A.. An adaptive dose-finding approach for correlated bivariate binary and continuous outcomes in phase I oncology trials. Statistics in Medicine. 2012.03; 31 (6): 516-532.

  11. Hirakawa A, Hamada C, Yoshimura I.. Sample size calculation through the incorporation of heteroscedasticity and dependence for a penalized t-statistic in microarray experiments. Journal of Biopharmaceutical Statistics. 2012.01; 22 (2): 260-275.

  12. Azuma Y, Hata K, Sai K, Udagawa R, Hirakawa A, Tohkin M, Ryushima Y, Makino Y, Yokote N, Fujiwara Y, Saito Y, Yamamoto H. Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer Biological & Pharmaceutical Bulletin. 2012; 35 (5): 717-724.

  13. Hashimoto K, Sasajima Y, Ando M, Yonemori K, Hirakawa A, Furuta K, Tsuda H, Fujiwara Y. Immunohistochemical profile for unknown primary adenocarcinoma PLoS ONE. 2012; 7 (1): e31181.

  14. Yonemori K, Hirakawa A, Ryushima Y, Saito M, Yamamotoro H, Hirata T, Ando M, Kodaira M, Yunokawa M, Shimizu C, Tamura K, Yamamoto H, Fujiwara Y. An analysis of guidance for proper usage documents for oncology drugs in Japan Pharmaceutical Medicine. 2012; 26 165-170.

  15. Yonemori K, Hirakawa A, Ando M, Hirata T, Yunokawa M, Shimizu C, Katsumata N, Tamura K, Yasuhiro F. Content analysis of oncology-related pharmaceutical advertising in a peer-reviewed medical journal PLoS ONE. 2012; 7 (8): e44393.

  16. Hashimoto K, Yonemori K, Katsumata N, Hirakawa A, Hirata T, Yamamoto H, Shimizu C, Tamura K, Ando M, Fujiwara Y. Use of squamous cell carcinoma antigen as biomarker of chemotherapy response in patients with metastatic cervical carcinoma European Journal of Obstetrics & Gynecology and Reproductive Biology. 2011.12; 159 (2): 394-398.

  17. Hirata T, Yonemori K, Hirakawa A, Shimizu C, Tamura K, Ando M, Katsumata N, Tanimoto M, Fujiwara Y. Efficacy of pleurodesis for malignant pleural effusions in breast cancer patients European Respiratory Journal. 2011.12; 38 (6): 1425-1430.

  18. Yonemori K, Tsuta K, Ando M, Hirakawa A, Hatanaka Y, Matsuno Y, Chuman H, Yamazaki N, Fujiwara Y, Hasegawa T. Contrasting prognostic implications of platelet-derived growth factor receptor-beta and vascular endothelial growth factor receptor-2 in patients with angiosarcoma Annals of Surgical Oncology. 2011.10; 18 (10): 2841-2850.

  19. Yonemori K, Hirakawa A, Ando M, Hirata T, Yunokawa M, Shimizu C, Katsumata N, Tamura K, Fujiwara Y. The notorious “drug lag” for oncology in Japan Investigational New Drugs. 2011.08; 29 (4): 706-712.

  20. Hirakawa A, Hamada C, Yoshimura I. Sample size calculation for a regularized t-statistic in microarray experiments. Statistics and Probability Letters. 2011.07; 81 (7): 870-875.

< PREV - NEXT >

To the head of this page.▲